Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results...
Finanical Reports
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report...
CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand
CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for...
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023
The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling...
Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...
Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting...
Kelun-Biotech Reports Robust 91.6% Revenue Growth Amid Strategic Licensing Efforts
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) reported its 2023 financial results, revealing revenues of...
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...
Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials
Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues...
3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics
3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...
Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...
China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...
WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles
WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results...
Akeso Biopharma Reports Record Revenue and First Profit, Driven by Innovative Drugs
Akeso Biopharma (HKG: 9926) has announced its financial results for 2023, reporting a record revenue...